A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1

NCT03905694 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hyperoxaluria
Primary Hyperoxaluria Type 1 (PH1)

Interventions

DRUG: Lumasiran

Sponsor

Alnylam Pharmaceuticals